Skip to main content
SpringerLink
Log in

Follow-up of Patients with Well-Differentiated Thyroid Cancer

  • Chapter
Thyroid Cancer

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Mazzaferri E (1995) Impact of initial tumor features and treatment selected on the long term course of differentiated thyroid cancer. Thyroid Today 28:1–13

    Google Scholar 

  2. Ron E, Lubin JH, Shore RE et al (1995) Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 141:259–277

    PubMed  Google Scholar 

  3. Tuttle RM, Becker DV (2000) The chernobyl accident and its consequences: update at the Millenium. Semin Nucl Med 30:133–140

    PubMed  Google Scholar 

  4. Samaan NA, Maheshwari YK, Nader S et al (1983) Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases. J Endocrinol Metab 56:1131–1138

    Google Scholar 

  5. Clarke SEM (1998) Radioiodine therapy of the thyroid. In: Murray IPC, Ell PJ (eds) Nuclear medicine in clinical diagnosis and therapy. Churchill and Livingstone, Edinburgh, pp 1049–1062

    Google Scholar 

  6. Mazzafferi EL, Kloos RT (2001) Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86:1447–1463

    Article  PubMed  Google Scholar 

  7. Hay ID (1989) Prognostic factors in thyroid carcinoma. Thyroid Today 12:1–9

    Google Scholar 

  8. Nygaards BJ, Hegedus L, Gervil M, Hjalgrim H, Soe-Jensen P, Hansen JM (1993) Radioiodine treatment of multinodular goiter. Br Med J 307:828–832

    Google Scholar 

  9. Mazzaferri E (1991) Treating differentiated thyroid carcinoma: where do we draw the line? Mayo Clin Proc 66:105–111

    PubMed  Google Scholar 

  10. DeGroot LJ, Kaplan EL, McCormick M, Straus FH (1990) Natural history, treatment and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71:414–424

    PubMed  Google Scholar 

  11. Maxon HR, Smith HS (1990) Radioiodine-131 in the diagnosis and treatment of well differentiated thyroid cancer. Endocrinol Metab Clin North Am 19:685–718

    PubMed  Google Scholar 

  12. Riccabona G (1998) Differentiated thyroid carcinoma. In: Murray IPC, Ell PJ (eds) Nuclear medicine in clinical diagnosis and therapy. Churchill and Livingstone, Edinburgh, pp 941–957

    Google Scholar 

  13. Goldman JM, Line BR, Aamodt RL et al (1980) Influence of triiodothyronine withdrawal time on 131-I uptake postthyroidectomy for thyroid cancer. J Endocrinol Metab 50:734–739

    Google Scholar 

  14. Clark OH, Duh QY (1990) Thyroid cancer. In: Green MA (ed) The thyroid gland. Raven, New York, pp 537–572

    Google Scholar 

  15. Sweeney D, Johnston G (2000) Radioiodine treatment of thyroid cancer-II. Maximizing therapeutic and diagnostic 131I uptake. In: Wartofsky L (ed) Thyroid cancer. a comprehensive guide to clinical management. Humana Press, Totowa, NJ, pp 239–250

    Google Scholar 

  16. Ladenson PW (2000) Recombinant thyrotropin versus thyroid hormone withdrawal in evaluating patients with thyroid carcinoma. Semin Nucl Med 30:98–106

    PubMed  Google Scholar 

  17. Haugen BR, Pacini F, Reiners C et al (1999) A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84:3877–3885

    Article  PubMed  Google Scholar 

  18. Harness JK, Fund L, Thompson NW, Burney RE, McLeod MK (1986) Total thyroidectomy: complications and technique. World J Surg 10:781–786

    Article  PubMed  Google Scholar 

  19. Clark OH, Elmhed J (1995) Thyroid surgery-past, present and future. Thyroid Today 38:1–9

    Google Scholar 

  20. Lennquist S (1986) Surgical strategy in thyroid carcinoma; a clinical review. Acta Chir Scand 152:321–338

    PubMed  Google Scholar 

  21. Massin JP, Savoie JC, Garnier H, Guiaraudon G, Leger FA, Bacourt P (1984) Pulmonary metastases in differentiated thyroid cacinoma,. Study of 58 cases with implications for the primary tumor treatment. Cancer 53:982–992

    PubMed  Google Scholar 

  22. Freitas JE, Gross MD, Ripley SD, Shapiro B (1986) Radionuclide diagnosis and therapy of thyroid cancer: current status report. In: Freeman LM (ed) Freeman and JohnsonÆs clinical radionuclide imaging. Grune and Stratton, Orlando, FL, pp 1994–2027

    Google Scholar 

  23. Shapiro B, Ruffini V, Jarwan A et al (2000) Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole body scans in patients with thyroid cancer. Semin Nucl Med 30:115–132

    PubMed  Google Scholar 

  24. Jeevanram RK, Shah DH, Sharma SM, Ganatra RD (1986) Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Nucl Med Biol 13:277–279

    Google Scholar 

  25. Park H (1992) Stunned thyroid after high-dose I-131 imaging. Clin Nucl Med 17:501–502

    PubMed  Google Scholar 

  26. Dadparvars S, Chevres A, Tulchinsky M, Krishna-Badrinath L, Khan AS, Slizofski WJ (1995) Clinical utility of technetium-99m methoxyisobutylisonitrite imaging in Differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na Scintigraphy and thyroglobulin quantitation. Eur J Nucl Med 22:1330–1338

    PubMed  Google Scholar 

  27. Kosuda S, Yokoyama H, Katayama M, Yokokawa T, Kusano S, Yamamoto O (1995) Technetium-99m tetrofosmin and technetium-99m sestamibi imaging of multiple metastases from differentiated thyroid carcinoma. Eur J Nucl Med 22:1218–1220

    PubMed  Google Scholar 

  28. Brendel AJ, Guyot M, Jeandot R, Lefolt G, Manicet G (1998) Thallium-201 imaging in the Follow-up of differentiated thyroid carcinoma. J Nucl Med 29:1515–1520

    Google Scholar 

  29. Szakall S, Esik O, Bajzik G, Repa I, Dabasi G, Sinkovacs I, Agoston P, Tron L (2002) 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 43:66–71

    PubMed  Google Scholar 

  30. Chin B, Patel P, Cohade C, Ewertz M, Wahl R, Ladenson P (2004) Recombinant humanthyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 89:91–95

    Article  PubMed  Google Scholar 

  31. Kang KW, Kim S-K, Kang H-S et al (2003) Prevalence and risk of cancer of focal thyroidincidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 88:4100–4104

    Article  PubMed  Google Scholar 

  32. Baudin E, Schlumberger M, Lumbrosa J et al (1996) Octreotide scintigraphy in patients with Differentiated thyroid carcinoma: contribution for patients with negative radioiodine scans. J Clin Endocrinol Metab 81:2451–2544

    Article  Google Scholar 

  33. Burch HB (2000) Papillary thyroid cancer. Follow up. In: Wartofsky L (ed) Thyroid cancer. a comprehensiveguide to clinical management. Humana Press, Totowa, NJ, pp 229–237

    Google Scholar 

  34. Fatourechi V, Hay ID (2000) Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance. Semin Nucl Med 30:107–114

    PubMed  Google Scholar 

  35. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M (2000) Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 85:175–178

    PubMed  Google Scholar 

  36. Van de Velde CJH, Hamming JF, Goslings BM, Schelfhout LJDM, Clark OH, Smets S et al (1988) Report of the consensus development conference on the management of differentiated thyroid cancer in the Netherlands. Eur J Cancer Clin Oncol 24:287–292

    Article  Google Scholar 

  37. Beierwaltes WH, Rabbini R, Dmuchowski C, Lloyd RV, Eyre P, Mallette S (1984) An analysis of ablation of thyroid remnants with 131I in 511 patients from 1947–1984. J Nucl Med 25:1287–1293

    PubMed  Google Scholar 

  38. Johnston G, Sweeney D (2000) Radioiodine therapy of thyroid cancer. General considerations. I. In: Wartofsky L (ed) Thyroid cancer. A comprehensive guide to clinical management. Humana Press, Totowa, NJ, pp 147–153

    Google Scholar 

  39. Grigsby PW, Baglan K, Siegel BA (1999) Surveillance of patients to detect recurrent thyroid carcinoma. Cancer 85:945–951

    PubMed  Google Scholar 

  40. Burman KD (1995) How serious are the risks of thyroid hormone over-replacement? Thyroid Today 18:1–9

    Google Scholar 

  41. Burmeister LA, Goumaz MO, Mariassh CN, Oppenheimer JH (1992) Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 75:344–350

    Article  PubMed  Google Scholar 

  42. Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, DeGroot LJ (1994) Serum thyrotropin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 79:98–105

    Article  PubMed  Google Scholar 

  43. Samaan NA, Schultz PN. Hickey RC, Haynie TP, Johnston DA, Ordonez NG (1992) Well-differentiated thyroid carcinoma and the results of various modalities of treatment. A retrospective review of 1,599 patients. J Clin Endocrinol Metab 75:714–720

    PubMed  Google Scholar 

  44. Benua RS, Cicale NR, Sonenberg M (1962) The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR 87:171–182

    Google Scholar 

  45. Hurley RJ, Becker DV (1983) The use of radioiodine in the management of thyroid cancer. In: Freeman LM, Weissman HS (eds) Nuclear medicine annual. Raven, New York, pp 348–349

    Google Scholar 

  46. Wartofsky L (2000) An approach ot the management of patients with scan negative, thyroglobulin positive, differentiated thyroid carcinoma. In: Wartofsky L (ed) Thyroid cancer. A comprehensive guide to clinical management. Humana Press, Totowa, NJ, pp 251–261

    Google Scholar 

  47. Deihl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, Lange H, Bredow J, Korber C, Grunwald F (2001) Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicenter study. Eur J Nucl Med 28:1671–1676

    Article  PubMed  Google Scholar 

  48. Lowe V, Mullan BP, Hay ID, McIver B, Kasperbauer JL (2003) 18F-FDG PET of patients with Hurthle cell carcinoma. J Nucl Med 44:1402–1406

    PubMed  Google Scholar 

  49. Tallroth E, Lundell G, Tennvall J, Wallin G (1990) Chemotherapy and multimodality treatment in thyroid carcinoma: disorders of the thyroid and parathyroid. II. Otolaryngol Clin North Am 32:523–527

    Google Scholar 

  50. White RL (2000) Management of papillary thyroid carcinoma. In: Wartofsky L (ed) Thyroid cancer. A comprehensive guide to clinical management. Humana Press, Totowa, NJ, pp 225–228

    Google Scholar 

  51. Eng C, Clayton D, Schuffenecker I et al (1996) The relationship between specific RET protooncogene mutations and diseased phenotype in multiple endocrine neoplasia type 2: international RET mutation consortium analysis. JAMA 276:1575–1579

    PubMed  Google Scholar 

  52. Ball DW (2000) Medullary thyroid carcinoma. In: Wartofsky L (ed) Thyroid cancer. A comprehensive guide to clinical management. Humana Press, Totowa, NJ, pp 365–381

    Google Scholar 

  53. Sisson JC (1989) Medical treatment of benign and malignant thyroid tumors. Endocrinol Metab Clin North Am 18:359–387

    PubMed  Google Scholar 

  54. Kwekkeboom DJ, Reubi JC, Lamberts SWJ et al (1993) In vivo somatostatin-receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 76:1413–1417

    PubMed  Google Scholar 

  55. Clarke SEM, Lazarus CR, Wraight P, Sampson C, Maisey MN (1988) Pentavalent [99m-Tc] DMSA, [131-I] MIBG, and [99m-Tc] MDP: an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid. J Nucl Med 29:33–38

    PubMed  Google Scholar 

  56. O'Byrne KJ, Hamilton D, Robinson I, Sweeney E, Freyne PG, Cullen MJ (1992) Imaging of medullary carcinoma of the thyroid using 111-In labeled anti-CEA monoclonal antibody fragments. Nucl Med Commun 13:142–148

    PubMed  Google Scholar 

  57. Clarke SEM, Lazarus CR, Edwards S et al (1987) Scintigraphy and treatment of medullary carcinoma of the thyroid with iodine-131 metaiodobenzylguanidine. J Nucl Med 28:1820–1825

    PubMed  Google Scholar 

  58. Virgolini I, Traub T, Novotny C, Leimer M, Fuger B et al (2001) New trends in peptidereceptor radioligands. Q J Nucl Med 45:153–159

    PubMed  Google Scholar 

  59. Hooft L, Hoekstra OS, Deville W, Lips P, Teule GJJ, Boers M, van Tulder MW (2001) Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow up of papillary or follicular cancer. J Clin Endocrinol Metab 86:3779–3786

    Article  PubMed  Google Scholar 

  60. Frilling A, Tecklenborg K, Gorges R, Weber F, Clausen M, Broelsch EC (2001) Preoperative diagnostic value of [18-F] Fluorodeoxyglucose positron emission tomography in patients with radio-iodine negative recurrent well-differentiated thyroid carcinoma. Ann Surg 234:804–811

    Article  PubMed  Google Scholar 

  61. Helal BO, Merlet P, Toubert M-E, Franc B, Schvartz C, Gauthier-Koelesnikov H, Prigent A, Syrota A (2001) Clinical impact of 18F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative 131I scanning results. J Nucl Med 42:1464–1496

    PubMed  Google Scholar 

  62. Wang W, Larson SM, Tuttle RM, Kalaigian H, Kolbert K, Sonenberg M, Robbins RJ (2001) Resistance of [18F]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 11:1169–1175

    Article  PubMed  Google Scholar 

  63. Clark OH, Hoelting T (1994) Management of patients with differentiated thyroid cancer who have positive serum thyroglobulin levels and negative radioiodine scans. Thyroid 4:501–505

    PubMed  Google Scholar 

  64. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J (1995) Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 80:1488–1492

    Article  PubMed  Google Scholar 

  65. Maxon HR III (1993) The role of I-131 in the treatment of thyroid cancer. Thyroid Today XVI:1–9

    Google Scholar 

  66. Schlumberger M, Arcangioli O, Pickarski JD, Tubiana M, Parmentier C (1988) Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med 29:1790–1794

    PubMed  Google Scholar 

  67. Beierwaltes WH (1978) The treatment of thyroid carcinoma with radioactive iodine. Semin Nucl Med 8:79–94

    PubMed  Google Scholar 

  68. Schlumberger MJ (1999) Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Invest 22:3–7

    PubMed  Google Scholar 

  69. Pacini F, Agate L et al (2001) Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic I-131 whole body scan: comparison of patients treated with high I-131 activities versus untreated patients. J Clin Endocrinol Metab 86:4092–4097

    Article  PubMed  Google Scholar 

Download references

Authors
  1. B. Shapiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Freitas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Gross
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Nuklearmedizin, Rheinische Friedrich-Wilhelms-Universität, Sigmund-Freud-Strasse 25, 53127, Bonn, Germany

    H.-J. Biersack (Professor Dr. med.) (Professor Dr. med.)

  2. Klinik für Nuklearmedizin, Universität Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany

    F. Grünwald (Professor Dr. med.) (Professor Dr. med.)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Shapiro, B., Freitas, J., Gross, M. (2005). Follow-up of Patients with Well-Differentiated Thyroid Cancer. In: Biersack, HJ., Grünwald, F. (eds) Thyroid Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-27845-1_12

Download citation

  • DOI: https://doi.org/10.1007/3-540-27845-1_12

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-22309-2

  • Online ISBN: 978-3-540-27845-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation